Successful spinal fusion by E. coli-derived BMP-2-adsorbed porous beta-TCP granules: a pilot study.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 19582526.
- Also identified by DOI 10.1007/s11999-009-0960-1 and PMC identifier 2772941.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Bone morphogenetic proteins (BMPs) were originally identified as osteoinductive proteins. With cloning of BMP genes, studies of BMPs and their clinical application have advanced. However, with increasing clinical applications, drug delivery systems and production costs have become more important issues. To address these issues, we asked whether E. coli-derived rhBMP-2 (E-BMP-2)-adsorbed porous beta-TCP granules could achieve posterolateral lumbar fusion in a rabbit model similar to autogenous bone grafts. Lumbar spinal fusion masses were evaluated by 3-D computed tomography, mechanical testing, and histological analyses 8 weeks after surgery. By these measures E-BMP-2-adsorbed beta-TCP granules achieved lumbar spinal fusion in dose-dependent fashion in a rabbit model as well as autogenous bone graft. Our preliminary findings suggest E-BMP-2-adsorbed porous beta-TCP could be a novel, effective alternative to autogenous bone grafting for generating new bone and promoting regenerative repair of bone, and potentially utilizable in the clinical setting for treating spinal disorders.
Medical subject headings
- Biocompatible Materials
- Bone Morphogenetic Protein 2
- Bone Transplantation
- Calcium Phosphates
- Drug Carriers
- Escherichia coli
- Lumbar Vertebrae
- Spinal Fusion
Anatomy
- lumbar spine